Skip to main content
Premium Trial:

Request an Annual Quote

Accler8 s Q1 Revenues Down, Net Loss Up 3 Percent

NEW YORK, Dec. 16 (GenomeWeb News) - Accelr8 Technology today said that total revenue for its first fiscal quarter fell to $21,724 revenue from $22,284 in the year-ago period.


Accler8's said 90 percent of its net revenues in the quarter were from sales to Schott, with whom it closed a microarray slide surface chemistry licensing agreement on Dec. 6.


Net loss for the quarter ending Oct. 31, meantime, increased to $509,800 from $494,761 year over year, the Denver-based company reported today.


The company reported research and development expenses of $203,000 for the quarter, a 42-percent increase over the $143,000 reported for the same quarter last year.


Acceler8 reported cash and cash equivalents of $6.8 million on hand as of Oct. 31.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.